Besponsa 1mg Injection

Besponsa 1mg Injection is given as an injection into veins by the healthcare provider. The dose will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it the wrong way or in more than the recommended dose can cause very serious side effects. It may take several weeks or months to see or feel the benefits but do not stop taking it unless your doctor tells you to.

This medicine's most common side effects include decreased blood cells (red cells, white cells, and platelets), infection, fatigue, hemorrhage, fever, nausea, headache, increased liver enzymes, and abdominal pain. If these bother you or appear serious, let your doctor know. There may be ways of reducing or preventing them.

Inform your doctor if you have a medical history of bleeding disorders, heart or liver disease, radiation treatment, or any other infection. Many other medicines can affect, or be affected by, this medicine, so let your doctor know about all the medications you are using. Inform the doctor immediately if you notice unusual bruising or bleeding, have dark, tarry, or bloody stools, and sore throat. This medicine reduces the number of blood cells in your blood, thereby increasing susceptibility to infections. Regular blood tests are required to check your blood cells along with the kidney, liver, and heart function during the treatment with this medicine. Effective contraception by males and females during the treatment with this medicine is important to avoid pregnancy.

• Acute lymphoblastic leukemia

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Your doctor or nurse will give you this medicine. Kindly do not self administer.

Besponsa 1mg Injection contains Inotuzumab Ozogamicin, an antineoplastic agent that treats relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL) in adults. targets CD22 antigen expressed on immature B-cell lymphocytes and blocks further growth of tumor cells. This medicine restores normal blood counts and helps achieve complete remission from the disease.